Traxoprodil

Traxoprodil

Traxoprodil
Systematic (IUPAC) name
(1S,2S)-1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidino)-1-propanol
Identifiers
CAS Registry Number  N
189894-57-3 (methanesulphonate)
ATC code None
PubChem CID:
IUPHAR/BPS
ChemSpider  YesY
UNII  YesY
KEGG  N
ChEMBL  YesY
Synonyms Traxoprodil, CP-101,606
Chemical data
Formula C20H25NO3
Molecular mass 327.416 g/mol
 N   

Traxoprodil (CP-101,606) is a drug developed by Pfizer which acts as an NMDA antagonist, selective for the NR2B subunit.[1][2] It has neuroprotective,[3] analgesic,[4] and anti-Parkinsonian effects in animal studies.[5][6] Traxoprodil has been researched in humans as a potential treatment to lessen the damage to the brain after stroke,[7][8][9][10] but results from clinical trials showed only modest benefit.[11]The drug was found to cause EKG abnormalities (QT prolongation) and its clinical development was stopped.[12] More recent animal studies have suggested traxoprodil may exhibit rapid-acting antidepressant effects similar to those of ketamine,[13] although there is some evidence for similar psychoactive side effects and abuse potential at higher doses,[14] which might limit clinical acceptance of traxoprodil for this application.

See also

References

  1. ^
  2. ^
  3. ^
  4. ^
  5. ^
  6. ^
  7. ^
  8. ^
  9. ^
  10. ^
  11. ^
  12. ^
  13. ^
  14. ^